MEI Pharma (MEIP) Competitors $5.16 -0.12 (-2.27%) Closing price 04:00 PM EasternExtended Trading$5.17 +0.01 (+0.19%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MEIP vs. TSHA, VIR, TERN, RLAY, SIGA, ORGO, MAZE, KROS, TRML, and ORKAShould you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include Taysha Gene Therapies (TSHA), Vir Biotechnology (VIR), Terns Pharmaceuticals (TERN), Relay Therapeutics (RLAY), Siga Technologies (SIGA), Organogenesis (ORGO), Maze Therapeutics (MAZE), Keros Therapeutics (KROS), Tourmaline Bio (TRML), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry. MEI Pharma vs. Its Competitors Taysha Gene Therapies Vir Biotechnology Terns Pharmaceuticals Relay Therapeutics Siga Technologies Organogenesis Maze Therapeutics Keros Therapeutics Tourmaline Bio Oruka Therapeutics Taysha Gene Therapies (NASDAQ:TSHA) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends. Which has stronger earnings & valuation, TSHA or MEIP? MEI Pharma has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$8.33M97.26-$89.30M-$0.34-8.74MEI Pharma$65.30M2.56$17.78M-$4.75-1.09 Which has more volatility & risk, TSHA or MEIP? Taysha Gene Therapies has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Do institutionals & insiders have more ownership in TSHA or MEIP? 77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 52.4% of MEI Pharma shares are owned by institutional investors. 3.8% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 3.1% of MEI Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor TSHA or MEIP? In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 3 articles in the media. Taysha Gene Therapies' average media sentiment score of 1.13 beat MEI Pharma's score of 0.82 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MEI Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer TSHA or MEIP? Taysha Gene Therapies presently has a consensus target price of $8.29, suggesting a potential upside of 178.98%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, research analysts plainly believe Taysha Gene Therapies is more favorable than MEI Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00MEI Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TSHA or MEIP more profitable? MEI Pharma has a net margin of 0.00% compared to Taysha Gene Therapies' net margin of -1,144.97%. MEI Pharma's return on equity of -77.00% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-1,144.97% -78.44% -44.82% MEI Pharma N/A -77.00%-64.79% SummaryTaysha Gene Therapies beats MEI Pharma on 10 of the 14 factors compared between the two stocks. Get MEI Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MEIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MEIP vs. The Competition Export to ExcelMetricMEI PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$170.90M$2.48B$5.74B$9.78BDividend YieldN/A1.67%4.40%4.04%P/E RatioN/A22.5330.8326.39Price / Sales2.56506.55382.9086.63Price / Cash0.88178.3537.7259.11Price / Book1.046.2910.106.62Net Income$17.78M$32.94M$3.26B$265.42M7 Day Performance12.42%2.27%3.91%3.58%1 Month Performance-23.44%1.06%3.74%0.46%1 Year Performance62.26%5.65%37.68%19.41% MEI Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MEIPMEI Pharma1.12 of 5 stars$5.16-2.3%N/A+66.0%$170.90M$65.30M0.00100TSHATaysha Gene Therapies3.317 of 5 stars$2.93-0.3%$8.29+182.8%+37.0%$631.10M$8.33M-8.62180Positive NewsVIRVir Biotechnology3.4374 of 5 stars$4.48-0.9%$30.25+575.2%-48.5%$627.90M$74.21M-1.12580News CoveragePositive NewsAnalyst UpgradeGap UpTERNTerns Pharmaceuticals3.755 of 5 stars$6.76-4.1%$15.63+131.1%-12.4%$616.95MN/A-6.5040RLAYRelay Therapeutics2.0685 of 5 stars$3.47-2.0%$17.25+397.1%-51.2%$610.34M$10.01M-1.78330News CoverageAnalyst ForecastAnalyst RevisionSIGASiga Technologies2.1385 of 5 stars$8.92+4.9%N/A-9.8%$608.65M$138.72M7.8940ORGOOrganogenesis4.3429 of 5 stars$4.58-3.2%$7.50+63.8%+59.1%$600.04M$482.04M-32.71950News CoveragePositive NewsMAZEMaze TherapeuticsN/A$13.35-1.1%$25.60+91.8%N/A$591.99M$167.50M0.00121News CoverageKROSKeros Therapeutics2.9553 of 5 stars$14.52+0.3%$30.00+106.6%-67.2%$588.11M$3.55M46.84100Positive NewsTRMLTourmaline Bio2.1398 of 5 stars$22.17-1.8%$50.14+126.2%+36.5%$579.72MN/A-6.4644ORKAOruka Therapeutics2.4855 of 5 stars$15.25-0.8%$40.38+164.8%N/A$575.62MN/A-5.43N/A Related Companies and Tools Related Companies Taysha Gene Therapies Alternatives Vir Biotechnology Alternatives Terns Pharmaceuticals Alternatives Relay Therapeutics Alternatives Siga Technologies Alternatives Organogenesis Alternatives Maze Therapeutics Alternatives Keros Therapeutics Alternatives Tourmaline Bio Alternatives Oruka Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MEIP) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access